Submissions for variant NM_000059.3(BRCA2):c.4578A>G (p.Thr1526=) (rs202022822)

Total submissions: 8

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Ambry Genetics	RCV000163588	SCV000214148	likely benign	Hereditary cancer-predisposing syndrome	2014-07-03	criteria provided, single submitter	clinical testing
Color	RCV000163588	SCV000683631	likely benign	Hereditary cancer-predisposing syndrome	2016-02-17	criteria provided, single submitter	clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System	RCV000427408	SCV000591910	benign	not specified	2012-10-01	criteria provided, single submitter	clinical testing
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)	RCV000495149	SCV000578012	benign	Breast-ovarian cancer, familial 2	2017-06-29	reviewed by expert panel	curation	Synonymous substitution variant, with low bioinformatic likelihood to alter mRNA splicing (splicing prior 0.02; http://priors.hci.utah.edu/PRIORS/) and frequency 0.0024 (East Asian), derived from ExAC (2014-12-17).
GeneDx	RCV000427408	SCV000515708	likely benign	not specified	2017-12-11	criteria provided, single submitter	clinical testing	This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Integrated Genetics/Laboratory Corporation of America	RCV000588843	SCV000694783	likely benign	not provided	2017-01-18	criteria provided, single submitter	clinical testing	Variant summary: The BRCA2 c.4578A>G (p.Thr1526Thr) variant causes a synonymous change involving a non-conserved nucleotide, 2/5 programs in Alamut predict that this variant may generate a novel 3' splicing acceptor site, one program also predicts the wild-type allele of this variant may generate the same 3' splicing acceptor site, suggesting this predicted effect is unlikely associated with the disease. However, these predictions have yet to be confirmed by functional studies. The variant of interest was observed in a large, broad control population, ExAC, with an allele frequency of 19/120502 (1/6369), predominantly in the East Asian cohort, 19/8642 (1/454), which exceeds the estimated maximal expected allele frequency for a pathogenic BRCA2 variant of 1/3333. Therefore, suggesting this is likely a benign polymorphism found primarily in population(s) of East Asian origin. Multiple publications have cited the variant in affected individuals, however, with limited available information (ie, lack of co-occurrence and cosegregation data). Multiple clinical diagnostic laboratories/reputable databases have classified the variant from "uncertain significance" to "likely benign/benign." Therefore, the variant of interest has been classified as "Likely Benign."
Invitae	RCV000204768	SCV000261061	benign	Hereditary breast and ovarian cancer syndrome	2017-12-20	criteria provided, single submitter	clinical testing
Laboratory of Molecular Diagnosis of Cancer,West China Hospital, Sichuan University	RCV000240740	SCV000265953	uncertain significance	Neoplasm of the breast	2015-11-01	criteria provided, single submitter	research